Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCC vs C-TPF in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01154920Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2010
- Primary completion
- Dec 2027
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Paclitaxel Micelles for Injection, carboplatin, KL-140, docetaxel, Cisplatin micelle injection (HA132) and 1 more in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2010; status: active, not recruiting.
02
Drugs
Paclitaxel Micelles for InjectioncarboplatinKL-140docetaxelCisplatin micelle injection (HA132)
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01154920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01154920.